Knowledge, Attitude, and Practices of General Neurologists and Headache Experts Toward Migraine Treatment: A Cross-Sectional Study in India Authors: Sanjith Aaron, Ashish Bondia, Ishan Patel, Vikas Madaan Published: 2026 ABSTRACT Background and Objectives:Migraine, a disabling neurological disorder, poses a significant global burden, especially among women of reproductive age. In India, inconsistent diagnoses and the underutilization of evidence-based therapies present substantial challenges. This study evaluated the knowledge, attitudes, and practices of general neurologists and headache experts in India regarding migraine diagnosis and treatment, identifying barriers and opportunities for improvement in clinical care.Methods:A cross-sectional online survey was conducted among 137 clinicians in India (125 general neurologists and 12 headache experts). The questionnaire assessed diagnostic approaches, preferences for pharmacological and non-pharmacological treatments, utilization of guidelines, and readiness to adopt novel therapies. Data were analyzed using descriptive statistics.Results:Headache experts reported a higher patient burden, with 9 (75.00%) seeing 25 or more headache patients per week, compared to 39 (31.2%) general neurologists. Migraines comprised over 50% of cases for 7 (58.33%) of the experts. The use of International Classification of Headache Disorders (3rd edition) criteria was markedly higher among headache experts (91.67% vs. 38.71%), as was the Migraine Disability Assessment (66.67% vs. 24.20%). Nonsteroidal anti-inflammatory drugs and triptans were the most commonly prescribed therapies. Although triptans provided only moderate relief for most patients, newer agents, such as ditans, were rarely used (0–20%). Nonpharmacological interventions were widely adopted, with approximately 90% usage in both groups. Barriers included limited diagnostic standardization, therapeutic inertia, low familiarity with newer agents, and operational challenges such as time constraints.Conclusions:Both general neurologists and headache experts acknowledge the burden of migraine and practice holistic management. However, gaps remain in standardized diagnosis, optimal triptan use, and the adoption of novel therapies. Enhancing clinician education, promoting validated diagnostic tools, developing expert consensus, and increasing community awareness are crucial to optimizing outcomes and reducing therapeutic inertia. Introduction Migraine is a debilitating neurological disorder characterized by episodes of moderate to severe headaches that typically last 4 to 72 hours, accompanied by symptoms such as photophobia, phonophobia, nausea, and vomiting.[1] Over 1.1 billion individuals globally are affected by migraine. Between 1990 and 2019, the global age-standardized prevalence of migraine increased by 1.7% (95% uncertainty interval [UI]: 0.7%–2.8%), indicating a rising public health burden. According to the Global Burden of Disease (GBD) Study 2019, migraine is the second leading cause of years lived with disability (YLDs) worldwide and the primary cause among women aged 15 to 49 years, accounting for 88.2% of the 46.6 million headache-related YLDs, which represents 5.4% of the total global YLDs.[23] In low- and middle-income countries, including India, migraine management is constrained by limited neurological resources, with only 0.1 neurologists per 100,000 population compared to 7.1 in high-income countries.[4] In India, migraine presents a substantial public health challenge, with prevalence rates ranging from 14.1% to 25.2%, and higher disability observed in women and rural populations (median of 24 headache days per year).[56] Affected individuals lose an average of 17.3 productive days annually, leading to a substantial economic burden.[7] Diagnostic challenges arise from symptom overlap and limited training, resulting in nearly half of migraines going unrecognized. This leads to prolonged suffering, increased disability, and substantial economic burdens. Targeted clinician training is essential to improve diagnostic accuracy and patient outcomes.[8] To ensure accurate diagnosis and appropriate management, migraines are classified according to the International Classification of Headache Disorders (ICHD-3), 3rd edition, developed by the International Headache Society (IHS).[9] Adherence to these standardized diagnostic criteria enhances diagnostic precision and reduces misclassification in both clinical and research settings. Conventional acute treatments, such as nonsteroidal anti-inflammatory drugs (NSAIDs), triptans, and ergotamines, offer moderate efficacy but carry risks of gastrointestinal adverse effects, cardiovascular diseases (CVDs), and medication-overuse headaches. Many patients experiencing inadequate relief continue to suffer from debilitating migraine attacks, underscoring the need for targeted therapies.[10] Novel targeted therapies, such as gepants and monoclonal antibodies, address the underlying pathophysiology of migraines by modulating the calcitonin gene-related peptide (CGRP) pathway. Gepants (e.g. rimegepant) have demonstrated significant efficacy and favorable safety profiles in acute migraine treatment.[11] These options provide individualized strategies to address unmet treatment needs, highlighting the clinical value of new CGRP receptor antagonists in migraine management. This study aimed to assess the knowledge, attitudes, and practices (KAP) of general neurologists and headache experts in India regarding migraine diagnosis and management. It includes the perceived burden of migraine, awareness of diagnostic tools, treatment guidelines, management strategies, and barriers to optimal care, with the goal of informing strategies to enhance awareness and improve patient outcomes. Methods Study design and setting A quantitative, cross-sectional, questionnaire-based survey was conducted by Christian Medical College (CMC) Vellore, in collaboration with the Consortium of Accredited Healthcare Organizations (CAHO), to assess the KAP of general neurologists and headache experts on migraine burden, diagnosis, and treatment in India. The study was designed and reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines in reporting cross-sectional observational research.[12] Participant selection Inclusion criteria Licensed general neurologists and headache experts practicing in both public and private sectors in India.Headache experts were neurologists from leading government institutions in India, recognized specialists with ≥5 years’ experience in headache clinics, and with at least one peer-reviewed publication or affiliation with headache societies. Licensed general neurologists and headache experts practicing in both public and private sectors in India. Headache experts were neurologists from leading government institutions in India, recognized specialists with ≥5 years’ experience in headache clinics, and with at least one peer-reviewed publication or affiliation with headache societies. Headache experts were neurologists from leading government institutions in India, recognized specialists with ≥5 years’ experience in headache clinics, and with at least one peer-reviewed publication or affiliation with headache societies. Actively involved in managing adult migraine patients and willing to provide informed consent for the online survey. Actively involved in managing adult migraine patients and willing to provide informed consent for the online survey. Exclusion criteria Interns, postgraduate trainees, or non-clinical researchers. Interns, postgraduate trainees, or non-clinical researchers. Incomplete survey responses. Incomplete survey responses. Duplicate entries (i.e., the same email or credentials used multiple times). Duplicate entries (i.e., the same email or credentials used multiple times). Sample size and recruitment Convenience and snowball sampling techniques were used to recruit participants from varied clinical settings. A total of 500 general neurologists and 20 headache specialists were invited; 125 general neurologists and 12 headache specialists completed the survey, yielding an overall response rate of 26.3% (25% and 60%, respectively). The unequal distribution reflects the low number of headache subspecialists in routine clinical practice in India. Comparisons between general neurologists and headache experts were descriptive and exploratory, aimed at identifying gaps in migraine care rather than drawing definitive inferential conclusions. Sample size calculation The sample size was calculated using the formula: n = Z2×p (1-p)/d2 where Z = 1.96 (for a 95% confidence level), p = the estimated proportion, and d = the margin of error (0.09). Among the KAP components, the maximum required sample size (n = 111 for practice) was considered, and a target of 110 participants was set. However, 137 complete responses were received and included in the final analysis. Questionnaire design and validation The structured questionnaire was developed based on a literature review of migraine management practices. It included items on demographics, diagnostic criteria, treatment preferences, and clinical practice patterns (Supplementary Material—Questionnaire). The tool was reviewed and validated by subject experts and pilot-tested on ten general neurologists at CMC, Vellore. Revisions were made based on face validity to ensure clarity and content validity. Data collection procedures Data were collected through an online survey (Google Forms and SurveyMonkey®) from October 2024 to April 2025. Participants were invited via email, which included an introductory message and the survey link. The first page contained study information and an electronic informed consent form. The questionnaire consisted mainly of predefined, checkbox-based items, with an “Others (please specify)” option allowing free-text responses where applicable. Only participants who provided consent were able to access the survey. Only complete, anonymized responses were analyzed, and duplicate entries were identified and removed. Ethical considerations The study received approval from the Institutional Review Board (IRB) of CMC, Vellore, India (IRB Min. No. 2410122, dated October 16, 2024). The study was conducted in accordance with the principles outlined in the ICH-GCP guideline,[13] ICMR National Ethical Guidelines (2017),[14] and NDCT Rules (2019).[15] Electronic informed consent was obtained from all participants. Participation was voluntary, confidentiality was strictly maintained, and participants were informed of their right to withdraw from the study at any time without consequences. Statistical analysis Data were summarized using descriptive statistics. Categorical variables were reported as frequencies and percentages. Missing data were handled using pairwise deletion. Results A total of 137 healthcare providers completed the study, comprising 125 general neurologists and 12 headache experts. Table 1 shows that most general neurologists had 6–10 years of clinical experience (47; 37.60%), whereas headache experts predominantly reported more than 16 years of practice (8; 66.67%). General neurologists were primarily affiliated with corporate hospitals (54; 43.20%), while headache experts (4; 33.33%) were more commonly associated with teaching hospitals or medical colleges. Experts also reported managing a higher weekly volume of migraine patients (10–25 patients/week: general neurologists 72 [57.60%] vs > 25 patients/week: headache experts 9 [75.00%]). Table 1Sociodemographic characteristicsParameterCategoryGeneral neurologists [n=125]Headache experts [n=12]Years of clinical experience<5 years22 (17.60)0 (0.00)6–10 years47 (37.60)2 (16.66)11–15 years24 (19.20)2 (16.66)>16 years32 (25.60)8 (66.67)Nature of practiceCorporate hospital54 (43.20)3 (25.00)Teaching hospital/Medical College24 (19.20)4 (33.33)Private practice attached to a small hospital (<100 beds)18 (14.40)1 (8.33)Public hospitals16 (12.80)1 (8.33)Standalone Outpatient Clinic6 (4.80)3 (25.00)Private Charitable Hospital/NGOs7 (5.60)0 (0.00)Number of headache patients seen in the outpatient department<10 patients per week14 (11.20)0 (0.00)10–25 patients per week72 (57.60)3 (25.00)>25 patients per week39 (31.20)9 (75.00)Patients who present with a headache suffering from migraine<1016 (12.80)1 (8.33)10–2550 (40.00)1 (8.33)25–5029 (23.20)3 (25.00)>5030 (24.00)7 (58.33)Number of migraine patients seen per week in the outpatient department5–1027 (21.60)1 (8.33)10–1551 (40.80)1 (8.33)15–2026 (20.80)3 (25.00)More than 2021 (16.80)7 (58.33)All values are presented as number (%). NGOs: Non-governmental organizations Sociodemographic characteristics All values are presented as number (%). NGOs: Non-governmental organizations Among general neurologists (n = 125), more than half (68; 54.40%) reported that 10%–25% of patients visiting them presented with headaches as their chief complaint. Similarly, 7 (58.33%) headache experts (n = 12) reported this range, while 5 (41.67%) reported an even higher proportion (25%-50%) of patients presenting with headache [Supplementary Figure 1]. Most general neurologists (50; 40.00%) reported that 10%–15% of their headache patients had migraine, whereas 7 (58.33%) headache experts indicated that more than 20% of headache patients had migraine [Figure 1]. These findings reflect a substantial burden of migraine, with respondents managing a considerable number of patients weekly. Proportion of headache patients diagnosed with migraine Most general neurologists (106; 85.00%) reported low aura prevalence (<40% of patients), whereas headache experts (11; 91.67%) more often observed aura in approximately 20% of patients. Episodic migraine (<15 days/month) was most frequently reported in 41%–60% of patients by general neurologists (41; 33.00%) and in 61%–80% by headache experts (7; 58.00%). Chronic migraine (>15 days/month) was commonly reported in 0–20% of patients by general neurologists (43; 34.00%) and in 21%–40% by headache experts (6; 50.00%) [Supplementary Table 1]. Supplementary Table 1Migraine presentation and patterns in clinical practiceParameterCategoryGeneral neurologists [n=125]Headache experts [n=12]Patients present with headache<104 (3.20)0 (0.00)10-2568 (54.40)7 (58.33)25-5044 (35.20)5 (41.67)>509 (7.20)0 (0.00)Migraine patients presenting with aura0 – 2073 (58.40)11 (91.67)21 – 4033 (26.40)1 (8.33)41 – 609 (7.20)0 (0.00)61 - 809 (7.20)0 (0.00)Migraine patients presenting without aura0 – 2019 (15.20)1 (8.33)21 – 4014 (11.20)1 (8.33)41 – 6019 (15.20)0 (0.00)61 - 8035 (28.00)4 (33.33)>8037 (29.60)6 (50.00)Patients with episodic migraine (<15 days/month)0 – 2025 (20.00)0 (0.00)21 – 4018 (14.50)3 (25.00)41 – 6041 (32.80)2 (16.67)61 - 8031 (24.80)7 (58.33)>809 (7.20)0 (0.00)Patients with chronic migraine (>15 days/month)0 – 2043 (34.40)2 (16.67)21 – 4038 (30.40)6 (50.00)41 – 6035 (28.00)2 (16.67)61 - 806 (4.80)2 (16.67)>802 (1.60)0 (0.00)Patients with familial history of migraine0 – 2035 (28.00)1 (8.33)21 – 4027 (21.60)7 (58.33)41 – 6047 (37.60)3 (25.00)61 - 8012 (9.60)1 (8.33)>804 (3.20)0 (0.00)Non-pharmacological advice113 (90.40)11 (91.67)Data presented as n (%) Migraine presentation and patterns in clinical practice Data presented as n (%) Among migraine-associated symptoms, the majority of general neurologists (110; 88.00%) and headache experts (9; 75.00%) reported that patients experienced a combination of symptoms such as nausea, photophobia, and phonophobia. Nausea alone, photophobia alone, and phonophobia alone were reported by 3 (2.40%), 1 (0.80%), and 2 (1.60%) general neurologists, respectively, and by 1 (8.33%), 1 (8.33%), and none of the headache experts, respectively [Figure 2]. Common symptoms associated with migraine In terms of migraine triggers, stress was the most commonly reported trigger (general neurologists 74 [59.20%]; headache experts 7 [58.33%]), followed by sleep deprivation (58 [46.40%]; 9 [75.00%]), sunlight exposure (38 [30.40%]; 8 [66.67%]), and food-related factors (46 [36.80%]; 3 [25.00%]). Travel and fasting were reported less frequently, while additional triggers were noted by 22 (17.60%) general neurologists and 6 (50.00%) headache experts [Supplementary Figure 2]. Regarding family history of migraine, most general neurologists (47; 37.60%) reported that 41–60% of patients had a positive family history, whereas 7 (58.33%) headache experts reported a prevalence of 21%–40%. Across both groups, mothers were the most commonly affected family members, followed by sisters, brothers, and fathers [Supplementary Table 1]. Adherence to ICHD-3 criteria was markedly higher among headache experts (11; 91.67%) than general neurologists (48; 38.71%). In contrast, general neurologists more frequently relied on non-standardized diagnostic approaches, such as clinical judgment (13; 10.48%) or other methods (26; 20.97%). Disability assessment tools such as Migraine Disability Assessment (MIDAS, 29; 23.39%) were primarily used to assess disease impact rather than for migraine diagnosis. Non-pharmacological advice was consistently high and comparable in both groups (general neurologists: 113 [90.40%]; headache experts: 11 [91.67%]). Yoga, exercise, and meditation were the most frequently recommended interventions, followed by stress avoidance, dietary adjustments, lifestyle modifications, and other measures. Moderate-to-high NSAID prescribing predominated in both groups, with general neurologists (41; 32.80%) most often reporting use in 61–80% of patients and headache experts (5; 41.67%) in 41%–80%. Very high use (>80%) was observed only among general neurologists. Ergot alkaloids and ditans were infrequently prescribed, with most respondents reporting use in 0–20% of patients [Supplementary Table 2a]. Supplementary Table 2aMigraine managementParameterCategoryGeneral neurologists [n=125]Headache experts [n=12]Patients treated with NSAIDs* (n=124)0–2021 (16.90)1 (8.33)21–4018 (14.50)1 (8.33)41–6026 (21.00)5 (41.67)61–8041 (33.10)5 (41.67)>8018 (14.50)0 (0.00)Patients treated using Ergot alkaloids0–20103 (82.40)11 (91.67)21–4015 (12.00)0 (0.00)41–604 (3.20)1 (8.33)61–802 (1.60)0 (0.00)>801 (0.80)0 (0.00)Patients Treated Using Ditans0–2091 (72.80)12 (100)21–4028 (22.40)0 (0.00)41–604 (3.20)0 (0.00)61–802 (1.60)0 (0.00)>800 (0.00)0 (0.00)Migraine patients self-medicate before consultation08 (6.40)0 (0.00)<106 (4.80)0 (0.00)10-3031 (24.80)2 (16.67)30-5050 (40.00)6 (50.00)>5030 (24.00)4 (33.33)Comorbidities restrict your prescription of medications/choice of medications of migraine treatment<1025 (20.00)2 (16.67)10-1552 (41.60)4 (33.33)15-2034 (27.20)4 (33.33)>2014 (11.20)2 (16.67)Data presented as n (%); *Missing data for some participants; n indicates available responses. NSAIDs: Non-Steroidal Anti-Inflammatory Drugs Migraine management Data presented as n (%); *Missing data for some participants; n indicates available responses. NSAIDs: Non-Steroidal Anti-Inflammatory Drugs Triptan use was more common at low patient proportions (<20.00%) among headache experts (8; 66.67%) compared to general neurologists (44; 35.20%), while moderate-to-high use (41%–80% of patients) was more common among general neurologists (60; 48.00%). High effectiveness in pain relief was the primary reason for prescribing triptans, reported by 98 (78.40%) general neurologists and 9 (75.00%) headache experts. Among headache experts, the availability of multiple triptan formulations was another key factor (6; 50.00% vs general neurologists 19; 15.2%). Oral tablets remained the preferred route in both groups (general neurologists: 114 [91.20%]; headache experts: 8 [66.67%]), followed by nasal sprays and oral dispersible (wafer) formulations, which were more commonly used by headache experts. Sumatriptan and rizatriptan were the most frequently prescribed agents in both groups (general neurologists: 92 [73.60%] and 75 [60.00%]; headache experts: 8 [66.67%] for both). Eletriptan was not reported in expert practice, while zolmitriptan was used only by headache experts (1; 8.33%). Pain relief rates clustered in the 50%–75% range for both groups (general neurologists: 56 [44.80%]; headache experts: 5 [41.67%]) [Figure 3]. Headache experts (5; 41.67%) more often advised switching triptans after ≥4 migraine episodes, whereas general neurologists (59; 47.20%) mostly switched after three episodes. Patients experiencing pain relief with triptan therapy Use of triptan monotherapy was low in both groups (≤20% of patients: general neurologists 70 [56.00%]; headache experts 7 [58.33%]), and combination therapy with NSAIDs was also generally low (0–20%: headache experts 8 [66.67%] vs general neurologists 51 [40.80%]) [Table 2]. Table 2Triptan prescribing patterns, treatment practices, and management approaches among general neurologists and headache expertsParameterCategoryGeneral neurologists [n=125]Headache experts [n=12]Patients treated using triptans0–2044 (35.20)8 (66.67)21–4014 (11.20)3 (25.00)41–6027 (21.60)1 (8.33)61–8033 (26.40)0 (0.00)>807 (5.60)0 (0.00)Reason for prescribing triptansHigh effectiveness in pain relief98 (78.40)9 (75.00)Rapid onset of action37 (29.60)5 (41.67)Ease of use29 (23.20)1 (8.33)Favorable safety profile20 (16.00)1 (8.33)Availability in various formulations (oral, nasal spray, injection)19 (15.20)6 (50.00)Familiarity and experience with the medication6 (4.80)1 (8.33)Others2 (1.60)0 (0.00)Route of administration of triptansOral tablets114 (91.20)8 (66.67)Nasal spray67 (53.60)6 (50.00)Oral dispersible tablets44 (35.20)5 (41.67)Wafer form of tablets10 (8.00)3 (25.00)Injectable19 (15.20)1 (8.33)Commonly used triptansSumatriptan92 (73.60)8 (66.67)Rizatriptan75 (60.00)8 (66.67)Almotriptan28 (22.40)3 (25.00)Eletriptan24 (19.20)0 (0.00)Zolmitriptan0 (0.00)1 (8.33)Patients experience pain relief with triptan treatment<309 (7.20)0 (0.00)30–5046 (36.80)6 (50.00)50–7556 (44.80)5 (41.67)>7514 (11.20)1 (8.33)Migraine episodes, do you advise your patient to take a triptan before changing to a different triptan or triptan formulations08 (6.40)0 (0.00)1 episode4 (3.20)1 (8.33)2 episodes28 (22.40)3 (25.00)3 episodes59 (47.20)3 (25.00)4 episodes26 (20.80)5 (41.67)Use of only triptans0–2070 (56.00)7 (58.33)21–4013 (10.40)3 (25.00)41–6022 (17.60)2 (16.67)61–8019 (15.20)0 (0.00)>801 (0.80)0 (0.00)Triptan in combination with NSAIDS0–2051 (40.80)8 (66.67)21–4019 (15.20)1 (8.33)41–6014 (11.20)2 (16.67)61–8033 (26.40)1 (8.33)>808 (6.40)0 (0.00)Number of different triptans or formulations tried before defining insufficient response08 (6.40)0 (0.00)113 (10.40)2 (16.67)285 (68.00)9 (75.00)319 (15.20)1 (8.33)Triptan contraindication in migraine patients<517 (13.60)2 (16.67)5–1040 (32.00)4 (33.33)10–1554 (43.20)3 (25.00)>1514 (11.20)3 (25.00)Number of patients who avoid triptan usagePregnancy100 (80.00)5 (41.67)Cerebrovascular diseases94 (75.20)11 (91.67)Elderly patients72 (57.60)9 (75.00)Coronary artery diseases98 (78.40)12 (100)Hypertension72 (57.60)9 (75.00)Patients with retinal migraine67 (53.60)7 (58.33)Basilar migraine57 (45.60)7 (58.33)Peripheral arterial disease0 (0.00)8 (66.67)Patients with triptan resistance or triptan insufficient response<1028 (22.40)1 (8.33)10–2049 (39.20)4 (33.33)20–3038 (30.40)2 (16.67)>3010 (8.00)5 (41.67)NSAIDs: Nonsteroidal anti-inflammatory drugs. Data presented as average proportions (%) Triptan prescribing patterns, treatment practices, and management approaches among general neurologists and headache experts NSAIDs: Nonsteroidal anti-inflammatory drugs. Data presented as average proportions (%) Both groups typically tried two triptans or formulations before deeming the response insufficient (general neurologists: 85 [68.00%]; headache experts: 9 [75.00%]). Contraindications such as coronary artery disease (CAD) (general neurologists: 98 [78.40%]; headache experts: 12 [100%]) and cerebrovascular disease (CVD) (general neurologists: 94 [75.20%]; headache experts: 11 [91.67%]) strongly influenced treatment avoidance. Insufficient response to triptans was reported in >30% of patients in headache expert practice (5; 41.67%), whereas it was most commonly reported in 10%–20% of patients by general neurologists (49; 39.20%) [Figure 4]. Self-medication before consultation was common, especially among patients of headache experts (6; 50.00%). Disability scales were used more frequently by headache experts (8; 66.67%) than general neurologists (30; 24.20%), with time constraints cited as a major barrier by general neurologists who did not use them (76; 80.90%). A small proportion also reported non-standardized approaches, such as migraine diaries, nerve testing, and IHS-related clinical methods, highlighting practice gaps and the need for focused medical education on standardized assessment tools. Comorbidities limited treatment options in 10%–15% of patients, as reported by 52 (41.60%) general neurologists and 4 (33.30%) headache experts [Supplementary Tables 2a and 2b]. Supplementary Table 2bMigraine managementParameterCategoryGeneral neurologists [n=124]Headache experts [n=12]Diagnostic tool or criteria usedICHD-348 (38.71)11 (91.67)MIDAS Criteria (disability assessment tool)†29 (23.39)0 (0.00)Clinical Related13 (10.48)1 (8.33)MIDAS Criteria, ICHD-38 (6.45)0 (0.00)None of the above26 (20.97)0 (0.00)Use of migraine disability assessment methodsYes30 (24.20)8 (66.67)No94 (75.80)4 (33.33)Type of disability assessment method used (Users) @n=30n=8MIDAS17 (56.67)3 (37.50)Migraine diary1 (3.33)0Nerve testing1 (3.33)0IHS-related clinical approach (non-scale)1 (3.33)0Not specified10 (33.33)0Other standardized tools (HIT-6, VAS)05 (62.50)Reasons for non-use of disability assessment methods# (Non-users)n=94n=4Time constraints76 (80.85)1 (25.00)Do not find it useful in practice14 (14.89)2 (50.00)Reason not specified4 (4.26)1 (25.00)*A combination of the above reasons8 (8.51)0Data presented as n (%); n indicates available responses. #Self-reported responses to an open-ended question reflecting routine practice. †MIDAS is a validated tool for assessing migraine-related disability and does not represent a diagnostic criterion. @Percentages calculated among respondents reporting use of disability assessment methods. #Percentages calculated among respondents not using disability assessment methods. *Multiple selections allowed. HIT-6: Headache impact test-6, ICHD-3: International classification of headache disorders, 3rd Edition, IHS: International headache society, MIDAS: Migraine disability assessment, VAS: Visual analog scale Migraine management Data presented as n (%); n indicates available responses. #Self-reported responses to an open-ended question reflecting routine practice. †MIDAS is a validated tool for assessing migraine-related disability and does not represent a diagnostic criterion. @Percentages calculated among respondents reporting use of disability assessment methods. #Percentages calculated among respondents not using disability assessment methods. *Multiple selections allowed. HIT-6: Headache impact test-6, ICHD-3: International classification of headache disorders, 3rd Edition, IHS: International headache society, MIDAS: Migraine disability assessment, VAS: Visual analog scale Triptan inadequate response or triptan resistance Experience-based stratification of general neurologists General neurologists with >10 years of practice more frequently employed combination and non-oral treatment strategies and reported a higher burden of triptan resistance and complex management needs. In contrast, clinicians with <10 years of experience demonstrated greater reliance on NSAIDs and oral formulations, and conducted fewer triptan trials before defining insufficient response. These findings reflected experience-dependent differences in prescribing patterns, treatment response, and the impact of comorbidities on therapeutic decision-making [Supplementary Tables 3a and 3b]. Supplementary Table 3aMigraine treatment patterns and triptan outcomes among general neurologists stratified by years of clinical experienceParameterCategory<10 Years of experience [n=68]>10 Years of experience [n=56]Acute migraine treatments prescribedNSAIDs61.2551.08Triptans44.2940.79Ergot Alkaloids10.3011.27Paracetamol41.1635.16Ditans15.1112.70Any other treatments42.0633.30Treatment strategyTriptans alone36.4928.46Triptan + NSAID combination48.7534.41Data presented as average proportions (%). NSAIDs: Non-Steroidal Anti-Inflammatory Drugs Migraine treatment patterns and triptan outcomes among general neurologists stratified by years of clinical experience Data presented as average proportions (%). NSAIDs: Non-Steroidal Anti-Inflammatory Drugs Supplementary Table 3bMigraine treatment patterns and triptan outcomes among general neurologists stratified by years of clinical experienceParameterCategory<10 Years of experience [n=68]>10 Years of experience [n=56]Pain relief with triptan therapy<30%7 (10.3)1 (1.8)30–50%28 (41.2)18 (32.1)50–75%26 (38.2)30 (53.6)>75%7 (10.3)7 (12.5)Triptan contraindications<10%31 (45.6)25 (44.6)10–20%36 (52.9)30 (53.6)20–30%1 (1.5)1 (1.8)>30%0 (0.0)0 (0.0)Triptan resistance / insufficient response<10%14 (20.6)14 (25.0)10–30%52 (76.5)34 (60.7)30–50%2 (2.9)7 (12.5)>50%0 (0.0)1 (1.8)Comorbidities restricting prescription choice<10%14 (20.6)11 (19.6)10–30%54 (79.4)45 (80.4)30–50%0 (0.0)0 (0.0)>50%0 (0.0)0 (0.0)Triptan formulations12 (3.2)2 (3.7)216 (25.4)12 (22.2)331 (49.2)28 (51.9)414 (22.2)12 (22.2)Triptan formulations before defining insufficient response16 (9.5)7 (13.0)250 (79.4)35 (64.8)37 (11.1)12 (22.2)40 (0.0)0 (0.0)Data presented as n (%) Migraine treatment patterns and triptan outcomes among general neurologists stratified by years of clinical experience Data presented as n (%) Discussion This cross-sectional study assessed the KAP of general neurologists and headache experts in India regarding migraine management, providing insights into clinical experience, practice settings, patient burden, diagnostic approaches, and treatment strategies. Headache experts provided more comprehensive care in specialty settings, whereas general neurologists in corporate hospitals often faced time constraints that limited detailed assessments. Headache experts demonstrated substantially higher adherence to the ICHD-3 diagnostic criteria (91.67%) compared with general neurologists (38.71%). In contrast, general neurologists more frequently relied on non-standardized approaches, including clinical judgment and disability assessment tools such as the MIDAS scale, which are intended to quantify disease impact rather than establish diagnosis. Approximately 23% of general neurologists reported using MIDAS as a diagnostic tool. Although this reflects self-reported practice rather than the intended role of MIDAS, it indicates a meaningful knowledge and implementation gap. Using a disability assessment tool instead of standardized diagnostic criteria may lead to misclassification, inconsistent treatment decisions, and variability in clinical practice, potentially affecting optimal patient care. Similar diagnostic gaps have been reported previously; a study in eastern India found that 25% of migraine cases were misdiagnosed by neurologists, emphasizing the need for standardized diagnostic training.[16] These findings highlight the need to strengthen awareness of the distinct roles of ICHD-3 criteria for diagnosis and tools such as MIDAS for disability assessment, particularly among general neurologists. Previous studies also indicate that a majority of neurologists (91%) correctly diagnose migraine based on clinical vignettes.[17] Standardized frameworks such as ICHD-3 improve diagnostic accuracy when combined with structured patient interviews and guide tailored acute treatment, appropriate prophylaxis, and integration of trigger management alongside non-pharmacological strategies to support comprehensive, patient-centered care.[18] Stress was the most frequently cited trigger (59.20% of general neurologists and 58.33% of headache experts), followed by sleep deprivation and sunlight exposure, consistent with previous studies identifying stress and sleep disturbances as key migraine triggers.[19] Nonpharmacological advice was provided at high rates in both groups, highlighting the importance of lifestyle modification and trigger avoidance in migraine management.[20] Pharmacological treatment patterns varied between groups. NSAID prescribing was common in both groups, with moderate-to-high use (41%–80%) most frequent, while very high use (>80%) was observed only among general neurologists. A study from a tertiary care hospital in Bhubaneswar, India, reported frequent NSAID use, with naproxen being the most commonly prescribed, followed by ibuprofen and etoricoxib.[21] Triptans were prescribed at moderate-to-high levels more often by general neurologists (48.00% for 41%–80% of patients) compared to headache experts, among whom low use (0–20%) was more common (66.67%). This could reflect differences in patient severity, as headache experts may reserve triptans for specific cases due to contraindications.[22] Oral tablets and nasal sprays were the most commonly preferred formulations; however, the higher use of wafer formulations by headache experts (25.00% vs. 8.00%) suggests greater familiarity with alternative delivery methods. Studies evaluating the efficacy and safety of triptans have predominantly focused on oral formulations, including tablets and orally disintegrating tablets. Contraindications such as CAD and CVD were major reasons for avoiding triptans, particularly among headache experts. A study showed that ≥20% of patients have a CVD that specifically contraindicates triptan use.[23] No general neurologists reported avoiding triptans in patients with peripheral arterial disease, indicating a critical knowledge gap in recognizing cardiovascular contraindications and the need for improved guideline awareness and risk stratification. Triptan resistance was more prevalent in headache expert practice (41.67% reporting >30%) than among general neurologists (39.20% reporting 10%–20%), possibly due to the higher proportion of chronic migraine and heavily pre-treated cases seen by headache experts. General neurologists used the MIDAS scale selectively rather than routinely due to time constraints, whereas higher rates of self-medication among patients of headache experts highlight the need for better patient education to prevent medication overuse. A systematic review and meta-analysis by Rashid et al.[24] reported a high prevalence of self-medication (53.57%), with headache as a common indication and NSAIDs among the most frequently used drugs. Although triptans are widely used for acute migraine, the absence of standardized national guidelines in India leads to variability in defining treatment response.[25] Most general neurologists (68.00%) and headache experts (75.00%) required trials of two triptans or formulations before defining a patient as a “non-responder,” while smaller proportions did so after just one trial (10.40% vs. 16.67%). This inconsistency may contribute to triptan overuse and suboptimal outcomes in patients with inadequate relief, frequent relapse, or treatment-limiting adverse effects. International guidelines offer standardized criteria for assessing triptan efficacy. The European Headache Federation (2022) defines triptan responders as those achieving effective relief in ≥3 of 4 attacks, whereas the IHS (2024) evaluates response over three attacks and considers treatment ineffective if no meaningful benefit occurs in ≥2 attacks. Both recommend trying up to three triptans before switching classes.[2627] In contrast to these international recommendations, many Indian neurologists continue prescribing triptans beyond 3–4 episodes before switching, potentially prolonging patient suffering. In the present study, 47.20% of general neurologists continued triptans for three episodes and 20.80% for four episodes, compared with 25.00% and 41.67% of headache experts, respectively. With increasing experience, neurologists tend to adopt more targeted prescribing, optimize counseling and formulation selection, and trial multiple formulations before defining non-response, helping distinguish true resistance from suboptimal use. To address these challenges, a consensus framework developed with Indian headache experts is essential to standardize definitions of triptan response, non-response, and resistance. Clear and uniform criteria would help general neurologists identify non-responders early, optimize treatment duration, and guide systematic cycling across triptans. Such standardization would reduce undertreatment, avoid inconsistent switching, and prevent prolonged ineffective triptan use, supporting more rational, evidence-based, and patient-centered migraine management in India.[28] The addition of novel therapies such as CGRP antagonists, including gepants, offers a promising, targeted advancement in migraine management compared with conventional treatments. Evidence shows that these agents reduce attack frequency and symptom burden in patients who are unresponsive or intolerant to standard options. Integrating these agents into treatment regimens can improve disease control, enhance quality of life, and reduce reliance on acute medications, thereby lowering the risk of medication overuse and related complications.[29] Overall, the observed differences in diagnostic and treatment practices highlight the need for improved training, wider use of ICHD-3 criteria, and better resource allocation for migraine care in India. Strengthening Continuing Medical Education (CME) programs, expanding headache services, and promoting structured assessments may enhance timely and effective management. Limitations The findings related to headache experts were compared with those of general neurologists to identify gaps in current migraine care in the country. However, voluntary online recruitment and self-reported data may introduce selection and reporting bias, thereby limiting generalizability. Furthermore, important migraine triggers such as menstruation[30] were not assessed in the survey. Additionally, attitudes toward migraine management were not assessed using validated Likert-scale instruments, limiting insights into clinician decision-making. Future studies should include larger, more balanced samples and longitudinal designs to evaluate evolving practice patterns. Conclusions This study highlights that both general neurologists and headache experts in India are aware of the burden of migraine and report using a combination of pharmacological and non-pharmacological strategies. However, differences exist in the use of diagnostic tools, treatment preferences, and adoption of newer therapies, including triptans. These findings highlight the need to enhance awareness and clinical familiarity with emerging migraine therapies. Continuous medical education programs and updated clinical resources may help bridge existing gaps and support evidence-based migraine management among physicians in India. Author contributions SA, IP, AB, and VM. were involved in study conception and design. SA and VM were involved in data collection. SA, IP, AB, and VM analyzed the data and were involved with manuscript preparation and critical revision. SA, IP, AB, and VM reviewed the manuscript. All the authors approved the final version of the manuscript. IP is a former Pfizer employee and contributed to the study design, protocol development, data analysis, and manuscript review. Conflicts of interest Authors AB and VM are full-time employees of Pfizer Limited, India, and hold stocks in Pfizer. IP is a former employee of Pfizer Limited, India. Data availability statement The data extracted for the analyses are available upon reasonable request from the corresponding author. Questionnaire Knowledge, Attitude and Practice (KAP) of Healthcare Providers Towards Migraine Prophylaxis and Treatment in India Demographics Years of clinical experience in your specialty: □ <5 years □ <5 years □ 6-10 years □ 6-10 years □ 11-15 years □ 11-15 years □ >16 years □ >16 years Nature of practice: □ Private practice attached to a small hospital (less than 100 beds) □ Private practice attached to a small hospital (less than 100 beds) □ Standalone Outpatient Clinic □ Standalone Outpatient Clinic □ Corporate hospital □ Corporate hospital □ Public hospital □ Public hospital □ Teaching hospital/Medical College □ Teaching hospital/Medical College □ Private Charitable Hospital/NGOs □ Private Charitable Hospital/NGOs Number of headache patients seen in OPD: □ <10 patients in a week □ <10 patients in a week □ 10-25 patients in a week □ 10-25 patients in a week □ >25 patients in a week □ >25 patients in a week Clinical Practice of Migraine Therapy – Statistics Please tick/ provide the best options/ answers: 1. In your overall clinical practice, what percentage of your patients present with headache: a) < 10% a) < 10% b) 10 - 25% b) 10 - 25% c) 25 - 50% c) 25 - 50% d) 50% d) 50% 2. What percentage of those seen with headache suffer from migraine? a) < 10% a) < 10% b) 10 - 25% b) 10 - 25% c) 25 - 50% c) 25 - 50% d) >50% d) >50% 3. What is the number of migraine patients you see in a week? a) 5-10 a) 5-10 b) 10-15 b) 10-15 c) 15-20 c) 15-20 d) More than 20 d) More than 20 4. What percentage of migraine patients present with and without aura? a) Migraine with aura - ______% a) Migraine with aura - ______% b) Migraine without aura - ______% b) Migraine without aura - ______% 5. What percentage of your patients have an episodic migraine and how many have chronic migraine? a) Episodic migraine (less than 15 days in a month): _____ % a) Episodic migraine (less than 15 days in a month): _____ % b) Chronic migraine (more than 15 days in a month): _____ % b) Chronic migraine (more than 15 days in a month): _____ % 6. What is the most common migraine associated symptoms? a) Nausea a) Nausea b) Photophobia b) Photophobia c) Phonophobia c) Phonophobia d) Combination of above-mentioned symptoms d) Combination of above-mentioned symptoms e) Others (Please specify) ________________________________ e) Others (Please specify) ________________________________ 7. What is the most common trigger/s of migraine in your patients? Please mention the top 3 triggers: a) ____________________________________________________ a) ____________________________________________________ b) ____________________________________________________ b) ____________________________________________________ c) ____________________________________________________ c) ____________________________________________________ 8. What percentage of patients have a relevant familial history for migraine? a) % a) % 9. If family history is present, then who are the likely member to be affected with migraine? a) Mother a) Mother b) Father b) Father c) Brother c) Brother d) Sister d) Sister e) Others (Please specify) _________________________________ e) Others (Please specify) _________________________________ Migraine Management 1. Which diagnostic tool or criteria do you use to diagnose migraine in your practice? a) ____________________________________________________ a) ____________________________________________________ 2. Do you always advise a non-pharmacological treatment for migraine patients? a) Yes a) Yes b) No b) No If Yes, what are the non-pharmacological interventions reported If Yes, what are the non-pharmacological interventions reported (please specify) _______________________________________ (please specify) _______________________________________ 3. For the treatment of acute migraine attacks, what pharmacological treatment do you advise? Class of treatmentPercentage of PatientsNSAIDSErgot AlkaloidsTriptansAny other treatmentsParacetamolDitansOthers (Please specify) 4 (a). If you are prescribing Triptans, what is the route of administration? a) Oral tablets a) Oral tablets b) Oral dispersible tablets b) Oral dispersible tablets c) Wafer form of tablets c) Wafer form of tablets d) Nasal spray d) Nasal spray e) Injectable e) Injectable 4 (b). Which of the following triptans do you prefer? □ Sumatriptan □ Sumatriptan □ Rizatriptan □ Rizatriptan □ Almotriptan □ Almotriptan □ Eletriptan □ Eletriptan 4 (c). What is the primary reason you prefer prescribing triptans for your patients? □ High effectiveness in pain relief □ High effectiveness in pain relief □ Rapid onset of action □ Rapid onset of action □ Familiarity and experience with the medication □ Familiarity and experience with the medication □ Ease of use □ Ease of use □ Availability in various formulations (oral, nasal spray, injection) □ Availability in various formulations (oral, nasal spray, injection) □ Favourable safety profile □ Favourable safety profile 5. In what percentage of patients do you use only Triptans? a) % a) % 6. In what percentage of patient do you use Triptan in combination with NSAIDs? a) % a) % 7. What percentage of patients are relieved with Triptan treatment? a) <30% a) <30% b) 30-50% b) 30-50% c) 50-75% c) 50-75% d) >75% d) >75% 8. What percentage of patients are Triptan resistant or Triptan insufficient response in your practice? a) <10% a) <10% b) 10-20% b) 10-20% c) 20-30% c) 20-30% d) More than 30% d) More than 30% 9. For how many episodes do you advice your patient to take triptan before changing to different triptan or triptan formulations? a) 1 a) 1 b) 2 b) 2 c) 3 c) 3 d) 4 d) 4 10. How many different Triptan or Triptan formulations do you prescribe before defining a patient as having Triptan insufficient response? a) 1 a) 1 b) 2 b) 2 c) 3 c) 3 11. What percentage of migraine patient have contraindication to use Triptan? a) Less than 5% a) Less than 5% b) 5-10% b) 5-10% c) 10-15% c) 10-15% d) More than 15% d) More than 15% 12. In your practice, what are the patients you would avoid Triptan usage? (you can choose more than one option) (you can choose more than one option) □ Elderly patients □ Elderly patients □ Pregnancy □ Pregnancy □ Cerebro vascular diseases □ Cerebro vascular diseases □ Patients with retinal migraine □ Patients with retinal migraine □ Basilar migraine □ Basilar migraine □ Coronary artery diseases □ Coronary artery diseases □ Hypertension □ Hypertension □ Peripheral arterial disease □ Peripheral arterial disease 13. What percentage of migraine patients in your practice self-medicate before consultation? a) <10% a) <10% b) 10-30% b) 10-30% c) 30 – 50% c) 30 – 50% d) >50% d) >50% 14. In your practice, do you use migraine scales/ score to diagnose? a) Yes a) Yes b) No b) No If Yes, please mention the name of the tool: ______________________ If Yes, please mention the name of the tool: ______________________ If No, then what are the difficulties you face for using it:Time constraintsDon’t find it useful in my practiceI use the assessment scale without any problemOthers (Please specify) ________________________________ If No, then what are the difficulties you face for using it: Time constraints Time constraints Don’t find it useful in my practice Don’t find it useful in my practice I use the assessment scale without any problem I use the assessment scale without any problem Others (Please specify) ________________________________ Others (Please specify) ________________________________ 15. What are the usual comorbidities you look for, before prescribing medication for migraine? Please specify: ____________________________________________ Please specify: ____________________________________________ 16. In your clinical practice what percentage of comorbidities restrict your prescription of medications / choice of medications of migraine treatment. a) < 10% a) < 10% b) 10 - 15% b) 10 - 15% c) 15-20% c) 15-20% d) > 20 d) > 20 Patients presenting with headache in the overall outpatient department visits Most frequent triggers of migraine attacks